论文部分内容阅读
目的 :对阿格列汀在对于2型糖尿病的临床疗效以及药物经济学效果上展开分析。方法 :选择2015年1月~2016年12月间我院收治的2型糖尿病患者进行选择,从中随机抽取120例为研究对象,双盲分为实验组、对照组两组,各60例,其中实验组设立为阿格列汀和二甲双胍联合用药,对照组为二甲双胍和安慰剂用药,两组患者一般资料间并无差异;比较两组患者用药后的生理指标差异以及药物经济学效果。结果 :从疗效以及成本两个方面进行分析,在服药12周时,实验组患者成本高于对照组,但其较于对照组的临床效果却并无明显差异;在24周后,实验组的成本较于对照组存在较小差异,但临床效果优于对照组;在服药36周、48周后,患者的临床效果远优于对照组,且成本较于实验前期低。结论:就药用效果成本两方面综合考虑,对于长期服药的2型糖尿病患者来说,服用阿格列汀是一项有效的投入,对于提升患者的生活质量有着积极的影响。
OBJECTIVE: To analyze the clinical efficacy of alogliptin in the treatment of type 2 diabetes mellitus and its economic effects. Methods: Patients with type 2 diabetes mellitus admitted to our hospital from January 2015 to December 2016 were selected. 120 patients were randomly selected as the study subjects. The patients were divided into experimental group and control group with 60 patients in each group, double-blind The experimental group was established as the combination of alogliptin and metformin, and the control group was metformin and placebo. There was no difference between the two groups in the general data. The differences of the physiological indexes and pharmacological effects were compared between the two groups. Results: From the aspects of curative effect and cost, the cost of experimental group was higher than that of control group at 12 weeks of medication, but no significant difference compared with that of control group. After 24 weeks, the cost of experimental group The cost was lower than that of the control group, but the clinical effect was better than that of the control group. The clinical effect of the patients was much better than that of the control group after 36 weeks and 48 weeks of administration, and the cost was lower than that of the pre-experiment. CONCLUSIONS: Considering both the cost-effectiveness of drugs, taking alogliptin as an effective input for long-term type 2 diabetes patients has a positive impact on improving patients’ quality of life.